USA - NASDAQ:CDNA - US14167L1035 - Common Stock
The current stock price of CDNA is 14.52 USD. In the past month the price decreased by -1.02%. In the past year, price decreased by -38.6%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 22.85 | 381.38B | ||
| AMGN | AMGEN INC | 13.57 | 159.73B | ||
| GILD | GILEAD SCIENCES INC | 15.02 | 152.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.29 | 108.11B | ||
| REGN | REGENERON PHARMACEUTICALS | 13.95 | 66.56B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 830.33 | 55.51B | ||
| ARGX | ARGENX SE - ADR | 62 | 51.19B | ||
| INSM | INSMED INC | N/A | 38.63B | ||
| ONC | BEONE MEDICINES LTD-ADR | 5 | 33.96B | ||
| NTRA | NATERA INC | N/A | 26.96B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.20B | ||
| BIIB | BIOGEN INC | 8.92 | 21.89B |
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in Brisbane California, California and currently employs 644 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. The company offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. The company also offers a diverse portfolio of digital solutions to transplant centers.
CAREDX INC
8000 Marina Blvd, 4th Floor
Brisbane California CALIFORNIA 94080 US
CEO: Reginald Seeto
Employees: 644
Phone: 14152872300
CareDx, Inc. operates as a transplant diagnostics company, which discovers, develops and commercializes diagnostic solutions. The company is headquartered in Brisbane California, California and currently employs 644 full-time employees. The company went IPO on 2014-07-17. The firm is focused on the discovery, development, and commercialization of clinically differentiated healthcare solutions for transplant patients and caregivers. The company offers testing services, products, and digital healthcare solutions along the pre- and post-transplant patient journey and is the provider of genomics-based information for transplant patients. Its commercially available post-transplant testing services consist of AlloSure Kidney, a donor-derived cell-free DNA, or dd-cfDNA, solution for kidney transplant patients, AlloMap Heart, a gene expression profiling solution for heart transplant patients, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Its lab product portfolio includes QTYPE, Olerup SSP and SBT, AlloSeq Tx, AlloSeq HCT, and AlloSeq cfDNA. The company also offers a diverse portfolio of digital solutions to transplant centers.
The current stock price of CDNA is 14.52 USD. The price decreased by -1.69% in the last trading session.
CDNA does not pay a dividend.
CDNA has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
CAREDX INC (CDNA) operates in the Health Care sector and the Biotechnology industry.
CAREDX INC (CDNA) has a market capitalization of 772.90M USD. This makes CDNA a Small Cap stock.
The outstanding short interest for CAREDX INC (CDNA) is 11.79% of its float.
ChartMill assigns a technical rating of 2 / 10 to CDNA. When comparing the yearly performance of all stocks, CDNA is a bad performer in the overall market: 76.32% of all stocks are doing better.
ChartMill assigns a fundamental rating of 5 / 10 to CDNA. CDNA has an average financial health and profitability rating.
Over the last trailing twelve months CDNA reported a non-GAAP Earnings per Share(EPS) of 0.65. The EPS increased by 242.11% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 15.16% | ||
| ROA | 11.63% | ||
| ROE | 15.79% | ||
| Debt/Equity | 0 |
15 analysts have analysed CDNA and the average price target is 22.95 USD. This implies a price increase of 58.06% is expected in the next year compared to the current price of 14.52.
For the next year, analysts expect an EPS growth of 1.06% and a revenue growth 11.33% for CDNA